Challenges that remain regarding the use of cfDNA for MRD detection in myeloma: cost and sensitivity

Overcoming the challenges in utilizing cfDNA in screening for lung cancerПодробнее

Multiple Myeloma: MRD Detection, Single Cell RNA Sequencing, and Cell Free DNAПодробнее

The value of CTCs and cfDNA as novel biomarkers in multiple myelomaПодробнее

MRD Monitoring in Acute Myeloid LeukemiaПодробнее

What are the challenges and possibilities of ctDNA to monitor response and relapse in MM?Подробнее

Approaching MRD in Multiple MyelomaПодробнее

Measuring MRD: methods and challengesПодробнее

Challenges associated with developing a standardized technique for MRD detection in myelomaПодробнее

Where does MRD belong as a tool in myeloma?Подробнее

Dr. Landgren Discusses MRD Detection for Multiple MyelomaПодробнее

The Challenges of Treating R/R MyelomaПодробнее

"Circulating tumour DNA: An increasingly powerful diagnostic tool for oncology" - Nitzan RosenfeldПодробнее

Challenges with diagnosing MDS and future outlooksПодробнее

MRD detection in myeloma: approval of NGS assay & questions for the clinicПодробнее

Predicting drug resistance using single cell RNA sequencing in myelomaПодробнее

If you have myeloma, should you undergo tests for DNA sequencing?Подробнее

Dory Abelman - Developing Less Invasive Detection Methods Using Blood Based Cell Free DNA TestsПодробнее

Clinical value of measurable residual disease assessment in multiple myelomaПодробнее

What’s new in minimal residual disease (MRD) detection in myeloma?Подробнее